相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
Stephan Petersenn et al.
PITUITARY (2020)
The real costs of acromegaly: analysis of different therapies
Michal Elbaum et al.
ENDOKRYNOLOGIA POLSKA (2019)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study
Eva Lesen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Annamaria Colao et al.
PITUITARY (2016)
The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis
G. A. Kanakis et al.
CLINICAL ENDOCRINOLOGY (2016)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
Akira Shimatsu et al.
ENDOCRINE JOURNAL (2013)
Effects of Lanreotide Autogel on Growth Hormone, Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: A 1-Year Prospective Multicenter Study
Roberto Attanasio et al.
Endocrine Practice (2013)
Cost of Clinical Management of Acromegaly in Spain
Montse Roset et al.
CLINICAL DRUG INVESTIGATION (2012)
Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly Clinical article
Nicholas F. Marko et al.
JOURNAL OF NEUROSURGERY (2012)
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Yasemin Tutuncu et al.
PITUITARY (2012)
Hypertension-related factors in patients with active and inactive acromegaly
Daniela Fedrizzi et al.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2011)
Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly
Z. Karaca et al.
CLINICAL ENDOCRINOLOGY (2011)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY-2011 UPDATE: EXECUTIVE SUMMARY
Laurence Katznelson et al.
ENDOCRINE PRACTICE (2011)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
Annamaria Colao et al.
CLINICAL ENDOCRINOLOGY (2009)
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?
Pamela U. Freda
CLINICAL ENDOCRINOLOGY (2009)
The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Acromegaly
Anat Ben-Shlomo et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2008)
Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly
Orsalia Alexopoulou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Somatostatin agonists for treatment of acromegaly
Anat Ben-Shlomo et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
Magdalene Andries et al.
CLINICAL ENDOCRINOLOGY (2008)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution
RS Jallad et al.
CLINICAL ENDOCRINOLOGY (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
SS Damjanovic et al.
CLINICAL ENDOCRINOLOGY (2005)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Cost-of-illness study in acromegalic patients in Italy
G Didoni et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results?
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
分享论文
